Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rocket Pharmaceuticals Inc RCKT

Healthcare Biotechnology
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic... see more

Recent & Breaking News (NDAQ:RCKT)

Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Business Wire May 4, 2023

Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference

Business Wire May 3, 2023

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire April 11, 2023

Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage

Business Wire April 4, 2023

Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference

Business Wire March 1, 2023

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Business Wire February 27, 2023

Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Business Wire February 9, 2023

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Business Wire February 7, 2023

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

Business Wire January 9, 2023

Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2023

Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

Business Wire December 22, 2022

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting

Business Wire December 12, 2022

Rocket Pharmaceuticals Completes Acquisition of Renovacor

Business Wire December 1, 2022

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2022

EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger -SPNE, PEBO, SBCF, RCKT

PR Newswire November 17, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBCF, RCKT, CLR, USER

PR Newswire November 16, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCKT, RCOR, SMBC, TALO

PR Newswire November 10, 2022

RENOVACOR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Renovacor, Inc. - RCOR

PR Newswire November 3, 2022

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Business Wire November 3, 2022

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

Business Wire November 3, 2022